Ebola virus disease (EVD) first appeared in 1976 in 2 simultaneous outbreaks in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter occurred in a village near the Ebola River, from which the disease takes its name. The mortality rate was around 90 percent. Although medical facilities have improved over the years, case fatality rates have varied from 25% to 90% in past outbreaks. EVD outbreak that began in February 2014 in Guinea, is the most prevalent EVD outbreak recorded in the history which spred to Liberia, Sierra Leone, Nigeria, Senegal, Spain, and the United States. It had common features with the outbreak in 1976. Zaire Ebola virus was isolated in both outbreaks with the disease onset in rural forest communities. The outbreaks were worsened because critically ill patients with severe systemic symptoms were brought to hospitals which infected hospital staff was unaware of the risks of being exposed to patient blood and body fluids without proper protection. Due to the common travel and general international contacts implicit in globalization, as well as the popularity of tourism, EVD is most certainly a threat to the people all over the world \[[@ref1], [@ref2], [@ref3], [@ref4]\]. In this review article, we planned to discuss the epidemiological, clinical and laboratory features and patient management of EVD based on literature.

Virology {#sec2-1}
========

The virus family *Filoviridae* includes 3 genera: *Cuevavirus*, *Marburgvirus*, and *Ebolavirus* (EBOV). There are 5 species that have been identified: Zaire, Bundibugyo, Sudan, Reston and Tai Forest in Ebolavirus. Zaire, Bundibugyo, and Sudan ebolaviruses have been associated with large outbreaks in Africa. The virus causing the 2014 West African outbreak belongs to the Zaire species. Fruit bats of the family *Pteropodidae* are the recognized reservoir of the virus. The EBOV genome is a negative-sense single-stranded RNA and contain viral envelope, matrix, and nucleocapsid components. It encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35, VP40, GP), transcription activator (VP30, VP24), and RNA-dependent RNA polymerase (L) \[[@ref1]\]. EBOV is listed as an agent included in WHO Risk Group 4 Pathogen requiring biosafety level 4-equivalent containment requiring Biosafety Level 4-equivalent containment, because of its high mortality rate.

Epidemiology {#sec2-2}
============

The initial outbreak of EVD occurred in Yambuku in the Northern Zaire. Disease had spred by close personal contact. This was the first recognition of the disease and the subtype was named Zaire Ebola Virus \[[@ref2]\]. In the same year, another unrelated virus, which resulted in epidemics in South Sudan, was identified as Sudan Ebola Virus \[[@ref3]\]. Of interest, some researchers suggested that EBOV outbreaks might be related to certain confluences of environmental and climatic conditions \[[@ref4]\].

Up to date, 25 outbreaks have been reported including the current outbreak (n=4,1976-1979; n=6, 1994-1996; n=9, 2000-2008, and n=6 after 2011 \[[@ref5], [@ref6]\]. Current outbreak has been the largest documented outbreak of EVD and involved the Zaire species of the virus. The outbreak has been mostly seen in Guinea, Liberia and Sierra Leone, which together account for over 99% of all cases \[[@ref7]\]. It is indicated that the exponential growth phase is over in Liberia, with an expected final attack rate of \~0.1-0.12 percent \[[@ref8]\]. The natural reservoir of Ebola virus has not been identified yet. However, it is believed that the first patient became infected through contact with an infected animal like a fruit bat or nonhuman primate. When an infection occurs in humans, the virus can be transmitted through direct contact with blood, body fuids of a EVD patient, needles or syringes that have been contaminated with the virus or infected fruit bats or primates. Ebola virus infection does not spread through contaminated air water, food, or by mosquito and other insects bites.

Once people recover from Ebola, they can no longer spread the virus to people through conventional routes. For instance, men who have recovered from the disease can still transmit the virus through their semen for up to 7 weeks after recovery from illness.

One EVD outbreak started in Guinea in late 2013 which was confirmed by the World Health Organization (WHO) in March 2014. As of March, 18 2015, 24.754 suspect cases and 10.236 deaths had been reported \[[@ref9]\]. The case-fatality rate is between 20% and 90% depending on the virus species \[[@ref10], [@ref11]\].

Zaire Ebola virus species has the highest mortality rate (60%-90%) followed by the Sudan Ebola virus species (40%-60%). The Bundibugyo virus species has caused only one outbreak to date, with a 25% mortality rate. In the current outbreak, when the first 9 months of data were reviewed case-fatality rate was reported as 70.8% \[[@ref12]\]. Centers for Disease Control and Prevention (CDC) recommends that travelers to Guinea, Liberia, and Sierra Leone protect themselves by avoiding contact with the blood and body fluids of the diseased people. Nigeria, Cameroon, Central African Republic, Ghana, Angola, Togo, United Republic of Tanzania, Ethiopia, Mozambique, Burundi, Madagascar and Malawi are also at risk for spread of the EVD.

Clinical manifestations {#sec2-3}
=======================

EVD is an acute hemorrhagic fever, that has an incubation period of 2 to 21 days (mean 4-10) which is characterized by 'flu-like' symptoms like fever, chills, malaise, and myalgia. The febrile state may be mild during the initial phase of the illness, but may manifest with an acute, and very worse onset with associated chills and rigors. The most commonly described symptoms are fever in combination with a maculopapular rash around the face, neck, trunk, and arms usually appearing by day 5-7 of the illness. The most common symptoms were fever, fatigue, vomiting, diarrhea, and anorexia in current outbreak in Africa.

A person who has fever or symptoms as severe headache, fatigue, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage; and an epidemiologic risk factor within the 21 days before the onset of symptoms must be kept under observation.

Viral hemorrhagic fever is the main finding. Because of thrombocythemiamucosal hemorrhage (especially in the conjunctiva), petechiae, ecchymosis, can be observed in patients with EVD. Massive hemorrhage, is usually observed only in fatal cases especially in the gastrointestinal system \[[@ref13], [@ref14]\]. Other than the blood system, there are also cardiac, renal, pulmonary, neurological, gastrointestinal, and hepatic involvements. Cardiac manifestations might be due to the hemodynamic changes due to severe hemorrhage or direct viral involvement of the heart. But the cardiopathy in Ebola virus infection is not clear and needs further study. Profound fluid losses from the gastrointestinal tract result in volume depletion, metabolic abnormalities such as hyponatremia, hypokalemia, and hypocalcemia, shock, and organ failure. The patients who have respiratory, neurological, or hemorrhagic symptoms have higher risk of death \[[@ref15]\]. Patients who survive from Ebola infection have been reported to show clinical improvement by the middle of the second week.

Diagnosis {#sec2-4}
=========

EVD usually presents with an acute viral prodrome. It is difficult to distinguish EVD from other infectious diseases such as malaria, typhoid fever, meningitis, shigellosis, leptospirosis and yellow fever. Therefore, travel and exposure history is very important when approaching a suspected patient returning from an endemic area.

As laboratory findings, leukopenia with lymphocytes and an increased percentage of granulocytes are common signs at the time of clinical presentation As the disease progresses, leukocytosis can develop with an increase in immature granulocytes. Thrombocytopenia is a persistent feature until death. Mildly elevated serum levels of alanine and aspartate aminotransferase (ALT, AST) are common findings. Jaundice is not commonly seen, and serum total bilirubin level is either normal or elevated in the early phase of the illness. Elevated blood urea nitrogen and creatinine are observed due to excessive fluid loss from diarrhea and vomiting without adequate volume replacement. Prolonged prothrombin time (PT), partial thromboplastin time (PTT), or bleeding and disseminated intravascular coagulation (DIC) can be seen \[[@ref16]\].

Antigen-capture enzyme-linked immunosorbent assay (ELISA) testing, IgM ELISA, polymerase chain reaction (PCR) and virus isolation tests are used as diagnostic tests to confirm infection. Laboratory diagnosis for EVD should be performed in a well-equipped laboratory with up to biosafety level 4 bio- contaminant facilities for viral culturing. WHO Risk Group 4 Pathogen requiring biosafety level 4-equivalent containment requiring Biosafety Level 4-equivalent containment, because of its high mortality rate.

There is no biosafety level 4 bio- contaminant facilities in Turkey so there is a need to establish a biosafety level-4 laboratory for further studies in Turkey.

Case definitions for EVD {#sec2-5}
========================

According to the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), a suspected case was defined as follows:

Any person, alive or dead, had or having a sudden onset of high fever and had contact with a patient who is suspected, probable or confirmed or a dead or sick animal from Ebola; or if any person with sudden onset of high fever with at least three of the following findings: severe headache, fatigue, anorexia/loss of appetite, lethargy, breathing difficulties, muscle pain, vomiting, diarrhea, abdominal pain, unexplained hemorrhage or any sudden death without any cause.

A probable case was defined as any suspected case who has had direct contact with the blood and body fluids of an individual diagnosed with Ebola or who has had close physical contact with an individual diagnosed with Ebola or who lived with or visited an Ebola-diagnosed patient while the patient was ill within the previous 21 days with no laboratory confirmation.

A confirmed case was defined as a suspected or probable case with a positive laboratory result.

On 27 October 2014, the CDC updated the case definitions and included the category of "Person Under Investigation (PUI)" described as: A person who has fever or symptoms, including severe headache, fatigue, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage; and an epidemiologic risk factor within the 21 days before the onset of symptoms.

A confirmed case was defined as a PUI with a positive laboratory confirmation of EBOV \[[@ref17]\].

Treatment {#sec2-6}
=========

The main strategies that is being offered to infected patients are symptomatic and supportive care, such as hydration, replacement of electrolytes, nutritional support, maintaining oxygen status and blood pressure and treating other infections. Currently there is no approved vaccine and standard treatment for EVD that has been validated in humans \[[@ref18], [@ref19]\].

Up to date there are two notable Ebola vaccine efforts. The first one is cAd3-ZEBOV and the second is the rVSV. Both vaccines are effective in nonhuman primates, but confirmation of effectiveness against the Ebola virus in humans requires further studies \[[@ref20]\].

As a result of quick recovery of one of the Dallas (Texas USA) nurses following the transfer of plasma from Ebola survivors; passive immunity has become a potential treatment for EVD \[[@ref21]\].

Because of the high mortality rate of EVD, many investigational treatments are underway. ZMapp, is an experimental biopharmaceutical drug under development for treatment of EVD. It contains three "humanized" monoclonal antibodies (mAbs) against the EBOV GP protein. These antibodies are produced in plants, specifically Nicotiana benthamiana \[[@ref22]\].

This drug was first used experimentally in humans during the 2014 West Africa EVD outbreak, but there is no randomized controlled trial to determine whether it works or it is safe enough to bring it on the market \[[@ref20], [@ref23]\]. In early August 2014, "ZMapp", was used to treat two American medical workers and one Spanish priest and three African doctors who had contracted the deadly EBOV. Except for the 75-year-old Spanish priest who died despite the ZMapp treatment, the other five were reportedly improved significantly after receiving ZMapp. This is the first time that a drug has shown therapeutic efficacy against EVD in human.

Favipiravir is a new antiviral drug. It can be used for the treatment of patients with Ebola virus, but it is teratogenic, embryotoxic and any clinical trial of favipiravir has not been performed in patients infected with the Ebola virus. It is approved by The Minister of Health, Welfare and Labor of Japan due to the epidemic in West Africa \[[@ref24]\].

Melatonin is a natural substance, which is synthesized at night by the pineal gland and intestinal cells among many other cell types. It has no known side effects, even at very high concentrations. Melatonin has significant and curative effects on all the relevant cells and systems and decreases the symptoms and increases the survival of those infected with the Ebola virus. It is expected that melatonin will help maximize the benefit of soon available treatments \[[@ref25]\].

Prevention {#sec2-7}
==========

Since Ebola virus infection is highly infectious and there are no standard treatments for EVD, isolation of infected individuals is very important. If a diagnosis of Ebola is being suspected, then, the patient should be isolated in a single room (with a private bathroom or covered bedside commode), and healthcare personnel should follow standard, contact, and droplet precautions, including the use of appropriate personal protective equipment (PPE). PPE should include double gloves, gown or coverall and apron, face mask, eye protection (goggles or face shield) head cover, and boots. when performing aerosol-generating procedures, the wearing N95 of or higher respirators is also suggested.

Before contact with patients, washing hands with soap and water or an alcohol-based hand sanitizer and wearing appropriate personal protective equipment are recommended. Once exposed to blood or body fluids of the unprotected patient, healthcare workers should thoroughly wash the exposure site with water and soap. Safety needles are recommended for venipuncture or blood samples.

A minimum volume of 4 mL of whole blood preserved with EDTA is preferred for Ebola testing. Specimens for shipment should be packaged following the basic triple packaging system that consists of a primary sealable container wrapped with absorbent material, secondary container (watertight, leak-proof), and an outer shipping package and should be shipped at 2-8°C or frozen on cold-packs.

The defined case should be isolated till two negative results within a single 48 hour period are obtained. If death occurs from a suspect case of EVD, dead body should be burned within 24 hours.

In hospitals, transport and movement of the patients out of the room should be limited to medically-necessary purposes. If transport or movement outside the room is necessary, patients sould wear a surgical mask \[[@ref26]\].

After returning from epidemic area, body temperature should be monitored for 21 days.

The Ebola virus is susceptible to many chemical agents. According to the WHO recommendations, environment contaminated with blood spill or body fluid can be cleaned up with 1:10 dilution and for surfaces 1:100 dilution of 5.25% household bleach applied for 10 minutes is required \[[@ref25]\].
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